Aviva PLC Has $11.95 Million Stake in Qiagen N.V. $QGEN

Aviva PLC reduced its position in shares of Qiagen N.V. (NYSE:QGEN) by 60.5% during the 2nd quarter, Holdings Channel.com reports. The firm owned 247,681 shares of the company’s stock after selling 380,046 shares during the period. Aviva PLC’s holdings in Qiagen were worth $11,947,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Envestnet Asset Management Inc. purchased a new position in shares of Qiagen during the first quarter valued at $13,463,000. New York State Common Retirement Fund boosted its position in Qiagen by 3.0% during the 1st quarter. New York State Common Retirement Fund now owns 125,126 shares of the company’s stock worth $5,024,000 after acquiring an additional 3,623 shares during the period. Edgestream Partners L.P. acquired a new stake in Qiagen during the 1st quarter worth about $3,029,000. Segall Bryant & Hamill LLC grew its stake in Qiagen by 15.8% during the 1st quarter. Segall Bryant & Hamill LLC now owns 175,656 shares of the company’s stock valued at $7,053,000 after acquiring an additional 23,967 shares in the last quarter. Finally, ANTIPODES PARTNERS Ltd acquired a new position in shares of Qiagen in the 1st quarter valued at about $94,000. Hedge funds and other institutional investors own 70.00% of the company’s stock.

Qiagen Price Performance

NYSE QGEN opened at $44.25 on Wednesday. Qiagen N.V. has a fifty-two week low of $37.63 and a fifty-two week high of $51.88. The stock’s 50-day moving average is $46.34 and its two-hundred day moving average is $46.54. The firm has a market cap of $9.84 billion, a P/E ratio of 26.14, a price-to-earnings-growth ratio of 2.48 and a beta of 0.64. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.61 and a quick ratio of 1.35.

Qiagen (NYSE:QGEN) last released its quarterly earnings results on Tuesday, November 4th. The company reported $0.61 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.58 by $0.03. Qiagen had a return on equity of 14.77% and a net margin of 18.30%.The company had revenue of $533.00 million during the quarter, compared to the consensus estimate of $525.68 million. During the same quarter in the prior year, the company posted $0.57 EPS. The firm’s revenue was up 6.2% on a year-over-year basis. Qiagen has set its FY 2025 guidance at 2.380-2.380 EPS. Q4 2025 guidance at 0.600-0.600 EPS. On average, analysts anticipate that Qiagen N.V. will post 2.26 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts recently commented on QGEN shares. UBS Group raised their price target on shares of Qiagen from $48.00 to $50.00 and gave the stock a “neutral” rating in a report on Thursday, August 7th. Wall Street Zen raised shares of Qiagen from a “hold” rating to a “buy” rating in a research note on Saturday, November 1st. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Qiagen in a research note on Wednesday, October 8th. Barclays set a $53.00 price objective on Qiagen and gave the company an “overweight” rating in a research report on Thursday, October 2nd. Finally, Cowen restated a “hold” rating on shares of Qiagen in a research note on Thursday, August 7th. Three investment analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. According to MarketBeat.com, Qiagen currently has a consensus rating of “Hold” and an average target price of $49.69.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.